Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3]. |
Cas No. | 2416595-46-3 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.